- Home
- APLT vs PLUR Comparison
APLT vs PLUR Comparison
Compare APLT & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- PLUR
- Stock Information
- Founded
- APLT 2016
- PLUR 2001
- Country
- APLT United States
- PLUR Israel
- Employees
- APLT N/A
- PLUR N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- APLT Health Care
- PLUR Health Care
- Exchange
- APLT Nasdaq
- PLUR Nasdaq
- Market Cap
- APLT 37.5M
- PLUR 41.9M
- IPO Year
- APLT 2019
- PLUR N/A
- Fundamental
- Price
- APLT $0.35
- PLUR $3.96
- Analyst Decision
- APLT Buy
- PLUR Strong Buy
- Analyst Count
- APLT 7
- PLUR 1
- Target Price
- APLT $6.10
- PLUR $12.00
- AVG Volume (30 Days)
- APLT 1.4M
- PLUR 17.1K
- Earning Date
- APLT 08-06-2025
- PLUR 05-13-2025
- Dividend Yield
- APLT N/A
- PLUR N/A
- EPS Growth
- APLT N/A
- PLUR N/A
- EPS
- APLT N/A
- PLUR N/A
- Revenue
- APLT $265,000.00
- PLUR $1,034,000.00
- Revenue This Year
- APLT $1,768.13
- PLUR $472.39
- Revenue Next Year
- APLT $292.85
- PLUR $254.29
- P/E Ratio
- APLT N/A
- PLUR N/A
- Revenue Growth
- APLT N/A
- PLUR 203.23
- 52 Week Low
- APLT $0.30
- PLUR $3.33
- 52 Week High
- APLT $10.62
- PLUR $7.13
- Technical
- Relative Strength Index (RSI)
- APLT 42.17
- PLUR 37.09
- Support Level
- APLT $0.34
- PLUR $4.04
- Resistance Level
- APLT $0.38
- PLUR $4.50
- Average True Range (ATR)
- APLT 0.02
- PLUR 0.40
- MACD
- APLT -0.00
- PLUR -0.05
- Stochastic Oscillator
- APLT 7.14
- PLUR 7.03
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.